Spesolimab - Boehringer Ingelheim
Alternative Names: BI 655130; Spesolimab-sbzo; SPEVIGOLatest Information Update: 16 May 2025
At a glance
- Originator Boehringer Ingelheim
- Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 36 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Generalised pustular psoriasis
- Phase III Pyoderma gangrenosum
- Phase II/III Hidradenitis suppurativa; Netherton Syndrome; Ulcerative colitis
- Phase II Crohn's disease; Palmoplantar pustulosis
- Discontinued Atopic dermatitis
Most Recent Events
- 11 Apr 2025 Boehringer Ingelheim completes a phase II/III Lunsayil LTE trial in Hidradenitis suppurativa in Canada, Singapore, Malaysia, Lithuania, South Korea, Japan, Bulgaria, Argentina, Spain, Poland, Germany, France, Australia, USA (SC) (NCT06241573)
- 05 Feb 2025 Launched for Generalised pustular psoriasis (In adults, In adolescents, In children) in Canada (IV)
- 05 Feb 2025 Launched for Generalised pustular psoriasis (In adults, In adolescents, In children, Prevention) in Canada (SC)